Table 1 Overview of neuro-oncology tumor entities which are included in the molecular tumor board
From: The role of molecular tumor boards in neuro-oncology: a nationwide survey
Diagnosis | Response | Percentage |
|---|---|---|
Glioblastoma WHO CNS grade 4 | 30/38 | 78,9% |
Diffuse midline glioma WHO CNS grade 4 | 28/38 | 73,7% |
Astrocytoma WHO CNS grade 4 | 26/38 | 68,4% |
Astrocytoma WHO CNS grade 3 | 23/38 | 60,5% |
Astrocytoma WHO CNS grade 2 | 16/38 | 42,1% |
Oligodendroglioma WHO CNS grade 3 | 21/38 | 55,3% |
Oligodendroglioma WHO CNS grade 2 | 15/38 | 39,5% |
Ependymoma WHO CNS grade 3 | 21/38 | 55,3% |
Ependymoma WHO CNS grade 2 | 14/38 | 36,8% |
Meningioma WHO CNS grade 3 | 21/38 | 55,3% |
Meningioma WHO CNS grade 2 | 14/38 | 36,8% |
Chordoma | 16/38 | 42,1% |
Others | 07/38 | 18.4% |